Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 3/20 | 0.60 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.59 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.36 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.36 |
| ▸ | F10 | P00742 | 2/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cariporide SCHEMBL39639 | 0.99 | SLC9A1 (0.61) | SLC9A1SLC9A2CNR2PLAUCA1 | |
| Cariporide SCHEMBL1229789 | 0.97 | SLC9A1 (0.60) | SLC9A1SLC9A2CNR2PLAUCA1 | |
| Cariporide SCHEMBL6261845 | 0.97 | SLC9A1 (0.63) | SLC9A1SLC9A2CNR2PLAUCA1 | |
| Cariporide SCHEMBL221094 | 0.97 | SLC9A1 (0.63) | SLC9A1SLC9A2CNR2PLAUCA1 | |
| Hydrochloric Acid SCHEMBL8816752 | 0.87 | SLC9A1 (0.47) | SLC9A1SLC9A2CNR2PLAUCA1 | |
| SCHEMBL8743805 | 0.86 | SLC9A1 (0.47) | SLC9A1SLC9A2PLAUCA1CA2 | |
| Hydrochloric Acid SCHEMBL8983516 | 0.85 | SLC9A1 (0.46) | SLC9A1SLC9A2PLAUCA1CA2 | |
| Hydrochloric Acid SCHEMBL8743814 | 0.85 | SLC9A1 (0.46) | SLC9A1SLC9A2PLAUCA1CA2 | |
| SCHEMBL8647598 | 0.84 | SLC9A1 (0.44) | SLC9A1SLC9A2CNR2PLAUCA1 | |
| Cariporide SCHEMBL936191 | 0.83 | ALDH1A1 (0.48) | SLC9A1SLC9A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088799-B2 | E.g., combination of cariporide and ramipril for preventing heart failure and other age-related organ dysfunctions, age-related disorders and for prolonging life | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-01-03 | — | — | US | disclosed |
| US-6844361-B2 | Pharmaceutical composition comprising a sodium hydrogen exchange inhibitor and an angiotensin converting enzyme inhibitor | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-18 | — | — | US | disclosed |
| US-20050009899-A1 | Pharmaceutical composition comprising a sodium hydrogen exchange inhibitor and an angiotensin converting enzyme inhibitor | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-13 | — | — | US | disclosed |
| US-20030158247-A1 | Pharmaceutical composition comprising a sodium hydrogen exchange inhibitor and an angiotensin converting enzyme inhibitor | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158247-A1 | Pharmaceutical composition comprising a sodium hydrogen exchange inhibitor and an angiotensin converting enzyme inhibitor | ACE, REN, ACE2 | SLC9A1 4/4885SLC9A2 8/4885CNR2 2914/4885 |
| US-20050009899-A1 | Pharmaceutical composition comprising a sodium hydrogen exchange inhibitor and an angiotensin converting enzyme inhibitor | ACE, REN, ACE2 | SLC9A1 4/4885SLC9A2 8/4885CNR2 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.